

Marburg virus disease: In a nutshell

Roy B

Corresponding author:

Dr. Bedanta Roy,
Associate Professor, Department of Physiology, Faculty of
Medicine, Quest International University, Ipoh, Perak,
Malaysia

Email: bedanta.roy@gmail.com [ORCID](#)

Information about the article:

Published online: June 25, 2023

Cite this article:

Roy B. Marburg virus disease: In a nutshell.
Journal of Biomedical Sciences. 2023;10(1):1-2

Publisher

Nepal Health Research Society, Bahundhara -6,
Gokarnesowor Municipality, Kathmandu, Nepal
eISSN 2382-5545, ISSN 2676-1343 (Print)

© The Author(s). 2023

Content licensing: CC BY 4.0

Marburg virus disease (MVD) is a highly infectious and severe illness caused by the Marburg virus (MARV), a member of the Filoviridae family. The disease was first identified during simultaneous outbreaks in 1967 in Marburg and Frankfurt, Germany, and Belgrade, Serbia. MVD is characterized by a rapid onset of symptoms and a high case fatality rate, making it a significant public health concern.

Marburg virus is a single-stranded RNA virus with a filamentous shape. It is closely related to the Ebola virus and shares many similarities in structure and pathogenesis. The natural reservoir hosts of MARV are believed to be fruit bats of the Rousettus genus, and transmission to humans occurs through direct contact with infected bats or their bodily fluids. Human-to-human transmission can occur through close contact with infected individuals, often in healthcare settings.

MVD typically presents with an abrupt onset of symptoms, including high fever, headache, severe malaise, muscle aches, and weakness. Gastrointestinal symptoms such as nausea, vomiting, and diarrhea are also common. Patients may develop severe hemorrhagic manifestations as the disease progresses, including bleeding from multiple sites, such as the gums, gastrointestinal tract, and injection sites. Organ dysfunction and shock may follow, leading to a high mortality rate exceeding 80%.

Early diagnosis of MVD is essential for appropriate management and control measures. Laboratory testing is required to confirm the presence of MARV. Diagnostic methods include polymerase chain reaction (PCR) assays, antigen detection, and serological tests to detect specific antibodies. Due to the potential for cross-reactivity with other viruses, confirmation through specialized reference laboratories is often necessary.

The treatment and management of Marburg virus disease (MVD) requires a comprehensive approach to provide supportive care, manage complications, and implement infection control measures to prevent further transmission. Currently, there is no specific antiviral treatment approved for MVD. Therefore, supportive care remains the cornerstone of management.

Maintaining hydration and electrolyte balance is crucial in managing MVD patients. Intravenous fluids and electrolyte replacement therapy are administered to correct dehydration and maintain proper organ function. Patients with MVD often experience fever, headache, muscle aches, and gastrointestinal symptoms. Appropriate symptomatic relief measures, such as antipyretics, analgesics, antiemetics, and anti-diarrheal

agents, are provided to alleviate discomfort. Adequate nutrition is essential for patients' recovery. Nutritional support, including oral intake or enteral feeding, should be provided based on the patient's ability to tolerate and absorb nutrients. Strict barrier nursing i.e., isolation precautions, including contact and droplet precautions, should be implemented to minimize the risk of transmission. Healthcare workers must use appropriate personal protective equipment (PPE), including gloves, masks, goggles, and gowns when caring for MVD patients.

Environmental decontamination also needs to be done to curb the spread of the infection. Contaminated surfaces and materials should be disinfected appropriately with appropriate disinfectants to prevent the spread of the virus. Safe burial practices is also an important measure. Proper handling and burial of deceased individuals are important to prevent further transmission. Safe burial practices should be followed, adhering to cultural and religious considerations while ensuring infection control. Various experimental therapies, including antiviral drugs and immunotherapies, are under investigation to treat MVD. These therapies target the virus or boost the patient's immune response. Antivirals such as NP-718-LNP, BCX4430 (Galidesivir), AVI-7288 alone or in combination with AVI-7287 as AVI-6003, Favipiravir (T-705), and GS-5734 (remdesivir) are under investigation.

Continued research into the pathogenesis, epidemiology, and treatment of MVD is essential for improving patient outcomes and developing effective interventions. Collaboration between international organizations, research institutions, and healthcare providers is crucial to share knowledge, resources, and expertise in combating MVD. Preventing MVD outbreaks requires a comprehensive approach. Strategies include public health education to raise awareness about the disease and its transmission modes and promote behavioral changes to reduce contact with potential reservoirs. Implementing strict infection control practices in healthcare settings, including proper isolation procedures and appropriate personal protective equipment, is vital to prevent nosocomial transmission. Ongoing surveillance, outbreak response preparedness, and research into effective vaccines and therapeutics are crucial components of controlling MVD.

In conclusion, the Marburg virus disease is a severe and often fatal illness caused by the Marburg virus. It poses a significant public health threat, particularly in areas where outbreaks have occurred. Early detection, strict infection control measures, and ongoing research efforts are essential to prevent and effectively manage future outbreaks of MVD.

Dr. Bedanta Roy
Deputy Editor,

Journal of Biomedical Sciences
25.6.2023

Keywords

Disease, infection, management, transmission, virus

Abbreviations

Acquired immunodeficiency syndrome (AIDS), Centers for Disease Control and Prevention (CDC), cytomegalovirus (CMV), Expanded Access- Investigational New Drug (EA-IND), Food and Drug Administration (FDA), Intravenous vaccinia immune globulin (VIGIV)

Availability of data and materials

Not applicable.

Competing interests

None declared.

Publisher's Note

NHRS remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The publisher shall not be legally responsible for any types of loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Author information

Dr. Bedanta Roy, Associate Professor, Department of Physiology, Faculty of Medicine, Quest International University, Ipoh, Perak, Malaysia [ORCID](#)